Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Ascendis Pharma A (ASND) over the last 12 years, with Q3 2025 value amounting to -$62.8 million.

  • Ascendis Pharma A's Income from Continuing Operations rose 4110.4% to -$62.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$234.2 million, marking a year-over-year increase of 4700.19%. This contributed to the annual value of -$398.7 million for FY2024, which is 2302.61% up from last year.
  • Per Ascendis Pharma A's latest filing, its Income from Continuing Operations stood at -$62.8 million for Q3 2025, which was up 4110.4% from -$35.3 million recorded in Q2 2025.
  • Ascendis Pharma A's Income from Continuing Operations' 5-year high stood at -$35.3 million during Q2 2025, with a 5-year trough of -$200.7 million in Q4 2022.
  • In the last 5 years, Ascendis Pharma A's Income from Continuing Operations had a median value of -$117.3 million in 2024 and averaged -$113.5 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first plummeted by 8596.18% in 2022, then soared by 6993.03% in 2025.
  • Quarter analysis of 5 years shows Ascendis Pharma A's Income from Continuing Operations stood at -$121.3 million in 2021, then tumbled by 65.42% to -$200.7 million in 2022, then soared by 59.64% to -$81.0 million in 2023, then skyrocketed by 52.12% to -$38.8 million in 2024, then plummeted by 62.01% to -$62.8 million in 2025.
  • Its Income from Continuing Operations stands at -$62.8 million for Q3 2025, versus -$35.3 million for Q2 2025 and -$97.3 million for Q1 2025.